Welcome to our dedicated page for Praxis Precision Medicines news (Ticker: PRAX), a resource for investors and traders seeking the latest updates and insights on Praxis Precision Medicines stock.
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is a clinical-stage biopharmaceutical company focused on central nervous system (CNS) disorders characterized by neuronal excitation–inhibition imbalance. The PRAX news page on Stock Titan aggregates company announcements, clinical updates, regulatory milestones and capital markets activity related to its precision neuroscience pipeline.
Investors and followers of Praxis can use this page to track developments across the company’s diversified CNS portfolio. News items include progress updates on late-stage product candidates such as ulixacaltamide for essential tremor, vormatrigine for focal onset seizures and generalized epilepsy, relutrigine for developmental and epileptic encephalopathies (DEEs), and elsunersen for early-onset SCN2A-DEE. Praxis frequently reports on Phase 2 and Phase 3 study readouts, FDA interactions such as pre-NDA meetings and Breakthrough Therapy Designations, and changes to registrational trial designs.
The feed also covers corporate and financial disclosures, including underwritten public offerings, at-the-market equity programs, and governance or leadership changes. Form 8-K filings referenced in press releases provide additional detail on clinical data, regulatory feedback and financing terms. Because Praxis emphasizes precision neuroscience and genetic epilepsies, its news often highlights mechanistic data, biomarker findings and functional outcomes in epilepsy and movement disorder studies.
By reviewing this PRAX news stream, readers can follow key catalysts such as NDA preparation, pivotal trial milestones, regulatory designations and capital raises that may influence the company’s trajectory as it advances its CNS portfolio. Bookmark this page to access an organized view of Praxis Precision Medicines’ latest public communications and disclosures.
Praxis Precision Medicines (NASDAQ: PRAX) has announced an upcoming Epilepsy Day on April 27, 2022, from 8:30 a.m. to 11:30 a.m. ET, held virtually and in New York City. This event will highlight the company's extensive epilepsy pipeline, the largest in the industry, and discuss clinical and regulatory strategies. Key opinion leaders like Dr. Jacqueline French and Dr. Daniel Friedman will share insights on advancements in epilepsy and unmet patient needs. A live webcast will be available on their website, with a replay accessible for 90 days.
Praxis Precision Medicines (NASDAQ: PRAX) has announced that data from its PRAX-944 essential tremor (ET) program will be showcased at the 2022 American Academy of Neurology Annual Meeting in Seattle from April 2-7, and virtually from April 24-26. Chief Medical Officer Bernard Ravina highlighted the need for better therapeutic options for ET, as current treatments often have poor tolerability. PRAX-944, a T-type calcium channel blocker, has shown promise in reducing tremor symptoms with acceptable safety profiles. The oral presentation is scheduled for April 6 at 5:06 PM PT.
Praxis Precision Medicines (NASDAQ: PRAX) announced its participation in a fireside chat at Stifel’s 4th Annual CNS Day on March 29, 2022, at 11:30 a.m. ET. The event will be accessible through a live webcast on the company’s website, with a replay available for 90 days post-event. Praxis focuses on developing therapies for central nervous system disorders by leveraging genetic insights into neuronal excitation-inhibition imbalances, targeting both rare and prevalent neurological and psychiatric conditions. For more details, visit www.praxismedicines.com.
Praxis Precision Medicines (NASDAQ: PRAX) will participate in the Neuropsych panel at Cowen’s 42nd Annual Healthcare Conference on March 7, 2022, at 9:10 a.m. ET. The event will be accessible via live webcast on the company's website, with a replay available for 30 days post-event. Praxis focuses on developing therapies for CNS disorders using genetic insights, addressing conditions such as epilepsy, psychiatric, and movement disorders. They currently have three clinical-stage product candidates.
Praxis Precision Medicines (NASDAQ: PRAX) provided a corporate update and reported financial results for Q4 and full year 2021. The company expects topline results for PRAX-114 Phase 2/3 Aria Study for Major Depressive Disorder in June 2022. As of December 31, 2021, Praxis had $275.9 million in cash, funding operations into Q2 2023. R&D expenses rose to $120.3 million for 2021, up from $45 million in 2020. Net loss for 2021 was $167.1 million, compared to $61.8 million the previous year. Upcoming milestones include multiple study results for psychiatric and movement disorders.
Praxis Precision Medicines (NASDAQ: PRAX) announced on February 22, 2022, that it will release its fourth quarter and full year 2021 financial results on February 28, 2022, prior to U.S. market opening. The company will provide a corporate update and report on recent business and pipeline advancements through a video presentation. Afterward, a live Q&A session will be held at 8:30 a.m. ET. Praxis focuses on developing therapies for CNS disorders linked to neuronal excitation-inhibition imbalance, with three clinical-stage product candidates.
Praxis Precision Medicines (NASDAQ: PRAX) announced positive results from a preclinical study of PRAX-562, a new sodium channel blocker targeting rare Developmental and Epileptic Encephalopathies (DEEs). The study showed robust antiseizure activity and improved tolerability compared to existing therapies. Praxis plans to initiate a Phase 2 trial in Q1 2022 for treating DEEs, supported by favorable data presented at the American Epilepsy Society Annual Meeting. PRAX-562 has received Orphan Drug Designation from the FDA, indicating its potential as a viable treatment for epilepsy.
Praxis Precision Medicines (NASDAQ: PRAX) will host a Movement Disorder Day on December 17, 2021, from 9:00 a.m. to 12:00 p.m. ET, both virtually and in New York City. The event will provide insights into the company’s Movement Disorder franchise, highlighting the Essential Tremor market and development plans for PRAX-944 and PRAX-114. Additionally, updates on the upcoming clinical study for PRAX-944 in Parkinson’s disease will be discussed. Webcast access will be available through the company's website, with a replay for 90 days.
Praxis Precision Medicines has appointed Megan Sniecinski as its new chief business officer, enhancing its executive leadership team. Promoting Alyssa Wyant to chief regulatory and quality officer and Karl Hansen, Ph.D. to chief technical operations officer reflects the company’s commitment to advancing its clinical-stage programs targeting central nervous system disorders. Sniecinski, with extensive experience in corporate development from her previous roles at BioCryst Pharmaceuticals and Merck, is expected to drive operational excellence and innovation within the company.
Praxis Precision Medicines (NASDAQ: PRAX) announced upcoming presentations at the American Epilepsy Society 2021 Annual Meeting from December 3-7, 2021. They will showcase data from rare disease programs, including PRAX-562, a sodium channel blocker, and a KCNT1 inhibitor. Presenters include senior scientists discussing the efficacy and potency of these treatments. Praxis also emphasizes their broad pipeline for rare epilepsies and ongoing collaborations to explore genetic influences on CNS disorders.